PPBT

Purple Biotech (PPBT)

Purple Biotech Ltd

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:PPBT

1 2 3 4 5 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/21	20 : 40	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:PPBT	Purple Biotech Ltd
2024/05/21	20 : 30	GlobeNewswire Inc.	Purple Biotech Reports First Quarter 2024 Financial Results	NASDAQ:PPBT	Purple Biotech Ltd
2024/04/25	20 : 00	GlobeNewswire Inc.	Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting	NASDAQ:PPBT	Purple Biotech Ltd
2024/03/28	20 : 00	GlobeNewswire Inc.	Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024	NASDAQ:PPBT	Purple Biotech Ltd
2024/03/14	20 : 30	GlobeNewswire Inc.	Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology	NASDAQ:PPBT	Purple Biotech Ltd
2024/03/07	06 : 06	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:PPBT	Purple Biotech Ltd
2024/03/06	06 : 00	Edgar (US Regulatory)	Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]	NASDAQ:PPBT	Purple Biotech Ltd
2024/03/05	21 : 58	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:PPBT	Purple Biotech Ltd
2024/03/05	21 : 55	GlobeNewswire Inc.	Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results	NASDAQ:PPBT	Purple Biotech Ltd
2024/02/27	21 : 10	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:PPBT	Purple Biotech Ltd
2024/02/27	21 : 00	GlobeNewswire Inc.	Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024	NASDAQ:PPBT	Purple Biotech Ltd
2024/02/13	21 : 10	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:PPBT	Purple Biotech Ltd
2024/02/13	21 : 00	GlobeNewswire Inc.	Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial	NASDAQ:PPBT	Purple Biotech Ltd
2024/02/01	21 : 40	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:PPBT	Purple Biotech Ltd
2024/02/01	21 : 40	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:PPBT	Purple Biotech Ltd
2024/02/01	21 : 30	GlobeNewswire Inc.	Purple Biotech Reaches Recommended Phase 2 Dose for NT219	NASDAQ:PPBT	Purple Biotech Ltd
2024/01/27	06 : 15	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:PPBT	Purple Biotech Ltd
2023/12/20	22 : 06	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:PPBT	Purple Biotech Ltd
2023/12/20	22 : 05	GlobeNewswire Inc.	Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors	NASDAQ:PPBT	Purple Biotech Ltd
2023/12/14	21 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:PPBT	Purple Biotech Ltd
2023/12/14	20 : 50	GlobeNewswire Inc.	Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial	NASDAQ:PPBT	Purple Biotech Ltd
2023/11/21	21 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:PPBT	Purple Biotech Ltd
2023/11/21	20 : 50	GlobeNewswire Inc.	Purple Biotech Reports Third Quarter 2023 Financial Results	NASDAQ:PPBT	Purple Biotech Ltd
2023/11/15	14 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:PPBT	Purple Biotech Ltd
2023/11/15	06 : 13	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:PPBT	Purple Biotech Ltd
2023/11/14	06 : 11	Edgar (US Regulatory)	Form F-1/A - Registration statement for certain foreign private issuers: [Amend]	NASDAQ:PPBT	Purple Biotech Ltd
2023/11/02	20 : 04	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:PPBT	Purple Biotech Ltd
2023/11/02	20 : 00	GlobeNewswire Inc.	Purple Biotech Fortifies NT219 Patent Protection	NASDAQ:PPBT	Purple Biotech Ltd
2023/11/01	05 : 30	Edgar (US Regulatory)	Form D - Notice of Exempt Offering of Securities	NASDAQ:PPBT	Purple Biotech Ltd
2023/10/31	05 : 30	Edgar (US Regulatory)	Form F-1 - Registration statement for certain foreign private issuers	NASDAQ:PPBT	Purple Biotech Ltd